News All News

More than three decades of research by Doug Melton, Catalyst Professor and co-director of the Harvard Stem Cell Institute, led to the launch of Semma Therapeutics and the development of a potential new treatment for Type 1 diabetes that uses stem cells to make healthy insulin-producing cells that can be transplanted into patients. The Blavatnik Biomedical Accelerator supported the research that led to the launch of Semma Therapeutics out of the Melton Lab.

A lab at Harvard T.H. Chan School of Public Health received industry-sponsored research and aims to translate discoveries about a protein that helps regulate metabolism and inflammation into novel therapeutics for obesity, heart disease, and age-related illnesses.

Islet-on-a-chip technology streamlines diabetes research

Technique could replace daily injections for diabetics